Claims:WE CLAIM:

1. A compound represented by Formula [11] or a salt thereof

(in the formula,
L1 represents a group represented by Formula [2a]

(in the formula, R3a, R4a, R5a, and R6a are the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; p1 represents an integer of 1 to 3; q1 represents an integer of 0 to 3; and r1 represents an integer of 1 to 6); and
L2 represents a group represented by Formula [2b]

(in the formula, R3b, R4b, R5b, and R6b are the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; p2 represents an integer of 1 to 3; q2 represents an integer of 0 to 3; and r2 represents an integer of 1 to 6); and
L3 represents a group represented by Formula [2c]

(in the formula, R3c, R4c, R5c, and R6c are the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; p3 represents an integer of 1 to 3; q3 represents an integer of 0 to 3; and r3 represents an integer of 1 to 6); and
A2 represents any one of the groups represented by Formulae [12] to [17]

(in the formulae, ? represents a binding position);
m represents an integer of 1 to 3))

2. The compound according to claim 1 or a salt thereof,
wherein L3 is a group represented by Formula [18c]

(in the formula, R5c and R6c may be the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; and r3 represents an integer of 1 to 6).

3. The compound according to claim 1 or 2 or a salt thereof,
wherein L1 is a group represented by Formula [18a]

(in the formula, R5a and R6a are the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; and r1 represents an integer of 1 to 6).

4. The compound according to any one of claims 1 to 3 or a salt thereof,
wherein L2 represents a group represented by Formula [18b]

(in the formula, R5b and R6b are the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; and r2 represents an integer of 1 to 6).

5. A compound represented by Formula [38] or a salt thereof.

6. The compound according to any one of claims 1 to 5 which is obtained by the method comprising:
(1) a step of reacting a compound represented by Formula [1] or a salt thereof

in the formula, R1 represents a hydrogen atom or an amino-protecting group; R2 represents a carboxyl-protecting group; L1 represents a group represented by Formula [2a]

in the formula, R3a, R4a, R5a, and R6a are the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; p1 represents an integer of 1 to 3; q1 represents an integer of 0 to 3; and r1 represents an integer of 1 to 6; and L2 represents a group represented by Formula [2b]

in the formula, R3b, R4b, R5b, and R6b are the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; p2 represents an integer of 1 to 3, q2 represents an integer of 0 to 3; and r2 represents an integer of 1 to 6; with a compound represented by Formula [3] or a salt thereof

in the formula, L3 represents a group represented by Formula [2c]

in the formula, R3c, R4c, R5c, and R6c are the same as or different from each other and represent a hydrogen atom or a C1-6 alkyl group; p3 represents an integer of 1 to 3; q3 represents an integer of 0 to 3; and r3 represents an integer of 1 to 6; A1 represents any one of the groups represented by Formulae [4] to [9]

in the formulae, ? represents a binding position; and R7’s are the same as or different from each other and represent a carboxyl-protecting group; and m represents an integer of 1 to 3; so as to obtain a compound represented by Formula [10] or a salt thereof;

in the formula, R1, R2, L1, L2, L3, A1, and m have the same definition as R1, R2, L1, L2, L3, A1, and m described above; and
(2) a step of deprotecting the compound represented by Formula [10] or a salt thereof,

in the formula, A2 represents any one of the groups represented by Formulae [12] to [17]

in the formulae, ? represents a binding position; and L1, L2, L3, and m have the same definition as L1, L2, L3, and m described above.

7. A complex of the compound according to claim 1 to 6 or the salt with a metal.

8. The complex according to claim 7, wherein the metal is a cytotoxic radioactive metal.

9. The complex according to claim 8, wherein the cytotoxic radioactive metal is ?-ray-emitting nuclide or ?-ray-emitting nuclide.

10. The complex according to any one of claims 8 or 9, wherein the cytotoxic radioactive metal is 90Y, 114mIn, 117mSn, 186Re, 188Re, 64Cu, 67Cu, 59Fe, 89Sr, 198Au, 203Hg, 212Pb, 165Dy, 103Ru, 149Tb, 161Tb, 212Bi, 166Ho, 165Er, 153Sm, 177Lu, 213Bi, 223Ra, 225Ac, or 227Th.

11. The complex according to any one of claims 8 to 10, wherein the cytotoxic radioactive metal is 64Cu, 67Cu, 90Y, 153Sm, 166Ho, 177Lu, or 225Ac.

13. The complex according to any one of claims 8 to 11, wherein the compound is 2,2',2''-(10-(2-(((R)-1-((2-(4-(4-(N-((S)-1-carboxy-2-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentanamido)ethyl)sulfamoyl)-3,5-dimethylphenoxy)butanamido)ethyl)amino)-1-oxo-3-sulfopropan-2-yl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid, and the cytotoxic radioactive metal is 177Lu.

14. A pharmaceutical composition comprising the complex according to any one of claims 9 to 13.

15. The pharmaceutical composition according to claim 14, wherein the pharmaceutical composition is an agent for treatment of a disease involving an integrin.

16. The complex according to claim 8, wherein the metal is a noncytotoxic radioactive metal.

17. The complex according to claim 16, wherein the noncytotoxic radioactive metal is a gamma ray-emitting nuclide or a positron-emitting nuclide.

18. The complex according to claim 16 or 17, wherein the noncytotoxic radioactive metal is 18F aluminum complex, 18F gallium complex, 18F indium complex, 18F lutetium complex, 18F thallium complex, 99mTc, 111In, 113mIn, 114mIn, 67Ga, 68Ga, 82Rb, 86Y, 87Y, 152Tb, 155Tb, 201Tl, 51Cr, 52Fe, 57Co, 58Co, 60Co, 82Sr, 85Sr, 197Hg, 44Sc, 62Cu, 64Cu, or 89Zr.

19. The complex according to any one of claims 16 to 18, wherein the noncytotoxic radioactive metal is 18F aluminum complex, 111In, 67Ga, 68Ga, 64Cu, or 89Zr.

20. The complex according to any one of claims 16 to 19, wherein the compound is 2,2',2''-(10-(2-(((R)-1-((2-(4-(4-(N-((S)-1-carboxy-2-(5-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)pentanamido)ethyl)sulfamoyl)-3,5-dimethylphenoxy)butanamido)ethyl)amino)-1-oxo-3-sulfopropan-2-yl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid, and the noncytotoxic radioactive metal is 68Ga.

21. A pharmaceutical composition comprising the complex according to any one of claims 16 to 20.

22. The pharmaceutical composition according to claim 21, wherein the pharmaceutical composition is an agent for diagnosis of a disease involving an integrin.

23. The pharmaceutical composition according to claim 15 or 22, wherein the disease involving an integrin is tumor.

Dated this 19 Day of August 2019
, Description:SEE UPLOADED DOCUMENTS